In the first head-to-head trial of its kind, people with obesity who took tirzepatide (sold under the brand names Mounjaro and Zepbound) lost more weight and inches from their waist than those who ...

While the drugs certainly contribute to weight loss and health gains, they also cause a decline in muscle that some doctors ...

We came across a bullish thesis on Novo Nordisk A/S (NVO) on Substack by Kontra Investments. In this article, we will summarize the bulls’ thesis on NVO.

President Trump shared an anecdote about a wealthy friend's experience with inflated drug prices in the U.S., prompting a ...

For the 2025 outlook, Novo Nordisk now expects 13-21% revenue increase at constant exchange rates (CER). Operating profit is expected at 16-24% growth. However, this forecast, 3% lower for revenue and ...

Roche plans to invest over $700 million in setting up a new plant in North Carolina and up to $550 million in expanding its Indianapolis diagnostics hub.

For the 2025 outlook, Novo Nordisk now expects 13-21% revenue increase at constant exchange rates (CER). Operating profit is ...

Both medications were prescribed as weekly injections for patients clinically classified as obese, and were recommended ...

The obesity drug helped people trim about two inches more off their waists than Wegovy in the first head-to-head study of the ...

The Trump administration on Monday singled out powerful new weight-loss drugs including Wegovy and Zepbound as targets in its ...

Trump shared the anecdote as he signed an order Monday intended to drastically reduce the price Americans pay for ...

Both the Mounjaro and Wegovy jabs used in the trial were found to be effective treatments for patients with obesity, but one ...